To evaluate whether blood CC12gene expression defines disease status (Stage I-IV, stable or progressive) and whether the blood CC12gene expression predicts response to therapeutic intervention.
ID
Source
Brief title
Condition
- Malignant and unspecified neoplasms gastrointestinal NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Blood CC12gene test signature to be an accurate test for diagnosis or for
determination of status of disease and response to therapy with a sensitivity
that exceeds that of current blood-based strategies (CEA).
Secondary outcome
NA
Background summary
To identify a PCR-based peripheral blood CC12gene test signature as an accurate
biomarker test for patients with proven colorectal cancer, and whether this
test will be able to predict clinical status and therapeutic response.
Study objective
To evaluate whether blood CC12gene expression defines disease status (Stage
I-IV, stable or progressive) and whether the blood CC12gene expression predicts
response to therapeutic intervention.
Study design
Prospective multi-cohort blood and tissue sample study.
Study burden and risks
No extra risk is associated with participation in this study besides one extra
venepuncture with the known risks.
Plesmanlaan 121
Amsterdam 1066 CX
NL
Plesmanlaan 121
Amsterdam 1066 CX
NL
Listed location countries
Age
Inclusion criteria
1. Histologically confirmed colorectal cancer
2. Evaluable disease
Exclusion criteria
1. Patients with non-invasive colorectal cancer.
2. Patients undergoing local excision for colorectal cancer.
3. Known history of HIV seropositivity.
4. Patient with other malignancies
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL57267.031.16 |